JP2024523558A5 - - Google Patents

Info

Publication number
JP2024523558A5
JP2024523558A5 JP2023579538A JP2023579538A JP2024523558A5 JP 2024523558 A5 JP2024523558 A5 JP 2024523558A5 JP 2023579538 A JP2023579538 A JP 2023579538A JP 2023579538 A JP2023579538 A JP 2023579538A JP 2024523558 A5 JP2024523558 A5 JP 2024523558A5
Authority
JP
Japan
Prior art keywords
alkyl
composition according
less
compound
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523558A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034574 external-priority patent/WO2022271861A1/en
Publication of JP2024523558A publication Critical patent/JP2024523558A/ja
Publication of JP2024523558A5 publication Critical patent/JP2024523558A5/ja
Pending legal-status Critical Current

Links

JP2023579538A 2021-06-22 2022-06-22 脳腫瘍の治療における使用のためのｅｇｆｒの（１ｈ－ピロロ［２，３－ｂ］ピリジン－１－イル）ピリミジン－２－イル－アミノ－フェニル－アクリルアミド阻害剤 Pending JP2024523558A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163213301P 2021-06-22 2021-06-22
US63/213,301 2021-06-22
US202163257907P 2021-10-20 2021-10-20
US63/257,907 2021-10-20
PCT/US2022/034574 WO2022271861A1 (en) 2021-06-22 2022-06-22 (1h-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl-amino-phenyl--acrylamide inhibitors of egfr for use in the treatment of brain tumors

Publications (2)

Publication Number Publication Date
JP2024523558A JP2024523558A (ja) 2024-06-28
JP2024523558A5 true JP2024523558A5 (enExample) 2025-06-30

Family

ID=82693978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579538A Pending JP2024523558A (ja) 2021-06-22 2022-06-22 脳腫瘍の治療における使用のためのｅｇｆｒの（１ｈ－ピロロ［２，３－ｂ］ピリジン－１－イル）ピリミジン－２－イル－アミノ－フェニル－アクリルアミド阻害剤

Country Status (7)

Country Link
US (1) US20240293405A1 (enExample)
EP (1) EP4358957A1 (enExample)
JP (1) JP2024523558A (enExample)
KR (1) KR20240055717A (enExample)
AU (2) AU2022297453A1 (enExample)
CA (1) CA3224994A1 (enExample)
WO (1) WO2022271861A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023283206A1 (en) * 2021-07-07 2023-01-12 Crimson Biopharm Inc. Crystalline polymorphs of epidermal growth factor receptor inhibitor, and compositions and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US20040171630A1 (en) * 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
US20070116643A1 (en) 2005-07-01 2007-05-24 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
CA2616366A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
CN101273024A (zh) 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
CN111875585B (zh) * 2014-06-12 2023-06-23 上海艾力斯医药科技股份有限公司 一类激酶抑制剂
WO2016105525A2 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
WO2017035753A1 (zh) * 2015-08-31 2017-03-09 无锡双良生物科技有限公司 2-芳胺基吡啶、嘧啶或三嗪衍生物及其制备方法和用途
US20210101881A1 (en) * 2018-02-12 2021-04-08 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Pyrimidine compound, preparation method thereof and medical use thereof

Similar Documents

Publication Publication Date Title
US20250034187A1 (en) Sting agonistic compound
JP5726190B2 (ja) タンパク質キナーゼ阻害剤としての化合物および組成物
JP6021805B2 (ja) 腫瘍治療剤
TW200803867A (en) Dosage forms and methods of treatment using a tyrosine kinase inhibitor
JP2008509187A5 (enExample)
WO2010031265A1 (zh) 用于治疗增生性疾病的药物组合物
JP2006501201A5 (enExample)
CN1511036B (zh) 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
EP2455080A1 (en) S1P1 receptor agonists for use in the treatment of multiple sclerosis
JP2024516353A5 (enExample)
EP2707001B1 (en) Method for treatment of solid malignancies including advanced or metastatic solid malignancies
JP2024522183A5 (enExample)
JP2005532397A5 (enExample)
NZ550174A (en) Combinations comprising a vasculostatic compound such as vatalanib and epothilones, and pharmaceutical uses thereof
RU2007106933A (ru) Ингибиторы hsp90
US20240277722A1 (en) Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent
JP2003516994A5 (enExample)
CA2635093A1 (en) Derivatives of sulindac, use thereof and preparation thereof
AU2009319050B2 (en) Pharmaceutical combinations comprising a pyrido [4, 3-d] pyrimidine derived Hsp90-inhibitor and a HER2 inhibitor
JP2010535203A5 (enExample)
JP2025502240A5 (enExample)
AU2003223958B2 (en) Combinations comprising epothilone derivatives and alkylating agents
ES2890924T3 (es) Derivados de imidazol para el tratamiento de la hipertensión y/o la fibrosis
TWI343258B (en) Combination comprising an active ingredient which decreases the activity of the epidermal growth factor (egf) and an epothilone derivative
US7754716B2 (en) Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor